Abstract:Epithelial-mesenchymal transition (EMT) contributes to tumor invasion, metastasis and drug resistance. AKT activation is key in a number of cellular processes. While many positive regulators for either EMT or AKT activation have been reported, few negative regulators are established. Through kinase cDNA screen, we identified brain-type creatine kinase (CKB or BCK) as a potent suppressor for both. As a ubiquitously expressed kinase in normal tissues, CKB is significantly downregulated in several solid cancer types. Lower CKB expression is significantly associated with worse prognosis. Phenotypically, CKB overexpression suppresses, while its silencing promotes, EMT and cell migration, xenograft tumor growth and metastasis of prostate cancer cells. AKT activation is one of the most prominent signaling events upon CKB silencing in prostate cancer cells, which is in line with prostate cancer TCGA data. EMT enhanced by CKB silencing is abolished by AKT inhibition. Mechanistically, CKB interacts with AKT and sequestrates it from activation by mTOR. We further elucidated that an 84aa fragment at C-terminus of CKB protein interacts with AKT's PH domain. Ectopic expression of the 84aa CKB fragment inhibits AKT activation, EMT and cell proliferation. Interestingly, molecular dynamics simulation on crystal structures of AKT and CKB independently demonstrates that AKT's PH domain and CKB's 84aa fragment establish their major interaction interface. In summary, we have discovered CKB as a negative regulator of EMT and AKT activation, revealing a new mode of their regulation . We have also demonstrated that CKB downregulation is a poor prognosticator, which is sufficient to promote prostate cancer progression.

Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation

Overexpression of Csk-binding protein contributes to renal cell carcinogenesis

Overexpression of Csk-binding Protein Decreases Growth, Invasion, and Migration of Esophageal Carcinoma Cells by Controlling Src Activation.

Sh3kbp1-Binding Protein 1 Prevents Epidermal Growth Factor Receptor Degradation by the Interruption of C-Cbl-Cin85 Complex

CREB‐binding Protein Regulates Lung Cancer Growth by Targeting MAPK and CPSF4 Signaling Pathway

Upregulation of PAG1/Cbp Contributes to Adipose-Derived Mesenchymal Stem Cells Promoted Tumor Progression and Chemoresistance in Breast Cancer

CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation

EGF-induced nuclear localization of SHCBP1 activates β-catenin signaling and promotes cancer progression

TACE-Mediated Ectodomain Shedding of the Type I TGF-b Receptor Downregulates TGF-b Signaling

New Tumor Suppressor Cxxc Finger Protein 4 Inactivates Mitogen Activated Protein Kinase Signaling

Acute Csk Inhibition Hinders B Cell Activation by Constraining the PI3 Kinase Pathway.

[Up-Regulation of ErbB3-binding Protein 1 Inhibits the Growth of Esophageal Carcinoma Cells].

C-terminal Binding Protein-2 Promotes Cell Proliferation and Migration in Breast Cancer Via Suppression of P16ink4a

SHCBP1 Promotes the Progression of Esophageal Squamous Cell Carcinoma Via the TGFβ Pathway

Camp-Response-element-binding-protein-binding Protein Silencing Inhibits Thrombin-Induced Endothelial Progenitor Cell Migration Via Downregulation of CXCR4 Expression

SH3 domain‐binding kinase 1 promotes proliferation and inhibits apoptosis of cervical cancer via activating the Wnt/β‐catenin and Raf/ERK1/2 signaling pathways

EB1 acts as an oncogene via activating beta-catenin/TCF pathway to promote cellular growth and inhibit apoptosis

CREB-binding Protein Silencing Inhibits Thrombin-Induced Endothelial Progenitor Cells Angiogenesis

SUMOylation of Csk Negatively Modulates its Tumor Suppressor Function.

Downregulation of CREB-binding protein expression inhibits thrombin-induced proliferation of endothelial cells: possible relevance to PDGF-B

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia